Applying the cell-based coagulation model in the management of critical bleeding

Anaesthesia and Intensive Care

Volumn 45, Issue 2, 2017, Pages 166-176

  Ho, K M ^a,b   Pavey, W ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b MURDOCH UNIVERSITY   (Australia)

Author keywords

Blood transfusion; Coagulation; Coagulation tests; Haemorrhage; Massive transfusion

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; FIBRINOGEN; FRESH FROZEN PLASMA; THROMBIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; CELL THERAPY; CLINICAL OBSERVATION; CLINICAL RESEARCH; CRITICAL ILLNESS; ERYTHROCYTE TRANSFUSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MANAGED CARE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; VISCOELASTICITY; BIOLOGICAL MODEL; BLOOD CLOTTING; BLOOD TRANSFUSION; HEMORRHAGE;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD TRANSFUSION; HEMORRHAGE; HUMANS; MODELS, BIOLOGICAL; PLATELET FUNCTION TESTS;

EID: 85016508255     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057x1704500206     Document Type: Review

References (87)

1. Sihler KC, Napolitano LM. Complications of massive transfusion. Chest 2010; 137:209-220.
2. Ho KM, Leonard AD. Concentration-dependent effect of hypocalcaemia on mortality of patients with critical bleeding requiring massive transfusion: a cohort study. Anaesth Intensive Care 2011; 39:46-54.
3. Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135:634-641.
4. Ho KM, Duff OC. Predictors of an increased in vitro thrombotic and bleeding tendency in critically ill trauma and non-trauma patients. Anaesth Intensive Care 2015; 43:317-322.
5. Desborough MJ, Stanworth SJ. Uses and abuses of fresh-frozen plasma for the prophylaxis of bleeding. Clin Med (Lond) 2013; 13:197-199.
6. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015; 313:471-482.
7. Nakayama Y, Nakajima Y, Tanaka KA, Sessler DI, Maeda S, Iida J et al. Thromboelastometry-guided intraoperative haemostatic management reduces bleeding and red cell transfusion after paediatric cardiac surgery. Br J Anaesth 2015; 114:91-102.
8. Harahsheh Y, Ho KM. Viscoelastic point-of-care testing to guide transfusion and antithrombotic therapy in perioperative and critically ill patients: are all parameters created equal? Anaesth Intensive Care 2016; 44:11-13.
9. Petricevic M, Konosic S, Biocina B, Dirkmann D, White A, Mihaljevic MZ et al. Bleeding risk assessment in patients undergoing elective cardiac surgery using ROTEM® platelet and Multiplate® impedance aggregometry. Anaesthesia 2016; 71:636-647.
10. Gibbs NM. Point-of-care assessment of antiplatelet agents in the perioperative period: a review. Anaesth Intensive Care 2009; 37:354-369.
11. Kong R, Trimmings A, Hutchinson N, Gill R, Agarwal S, Davidson S, Arcari M. Consensus recommendations for using the Multiplate® for platelet function monitoring before cardiac surgery. Int J Lab Hematol 2015; 37:143-147.
12. MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964; 202:498-499.
13. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145:1310-1312.
14. Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 2001; 21:1094-1096.
15. Ho KM, Tan JA. Can the presence of significant coagulopathy be useful to exclude symptomatic acute pulmonary embolism? Anaesth Intensive Care 2013; 41:322-327.
16. Senzolo M, Sartori MT, Lisman T. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? HPB (Oxford) 2009; 11:459-464.
17. Esmon CT. The protein C pathway. Chest 2003; 124:26S-32S.
18. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Mannucci PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol 2013; 59: 265-270.
19. Rautou P-E, Tatsumi K, Antoniak S, Owens AP 3rd, Sparkenbaugh E, Holle LA et al. Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury. J Hepatol 2016; 64:53-59.
20. Ho KM, Yip CB, Duff O. Reactive thrombocytosis and risk of subsequent venous thromboembolism: a cohort study. J Thromb Haemost 2012; 10:1768-1774.
21. Ho KM, Morgan DJ. Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: a post hoc analysis of a randomised controlled study. Anaesth Intensive Care 2014; 42:59-64.
22. Lindsay CR, Edelstein LC. MicroRNAs in platelet physiology and function. Semin Thromb Hemost 2016; 42:215-222.
23. Jy W, Gomez-Marin O, Salerno TA, Panos AL, Williams D, Horstman LL, Ahn YS. Presurgical levels of circulating cell-derived microparticles discriminate between patients with and without transfusion in coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2015; 149:305-311.
24. Lilly CM, Liu X, Badawi O, Franey CS, Zuckerman IH. Thrombosis prophylaxis and mortality risk among critically ill adults. Chest 2014; 146:51-57.
25. Ho KM, Chavan S, Pilcher D. Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest 2011; 140:1436-1446.
26. Stanworth SJ, Walsh TS, Prescott RJ, Lee RJ, Watson DM, Wyncoll D. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time. Crit Care 2011; 15:R108.
27. De Pietri L, Bianchini M, Montalti R, De Maria N, Di Maira T, Begliomini B et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63:566-573.
28. Alving BM, Baldwin PE, Richards RL, Jackson BJ. The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants. Thromb Haemost 1985; 54:709-712.
29. Smith SA. The cell-based model of coagulation. J Vet Emerg Crit Care (San Antonio) 2009; 19:3-10.
30. Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost 2007; 5:1106-1112.
31. Cramer TJ, Anderson K, Navaz K, Brown JM, Mosnier LO, von Drygalski A. Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male. Blood Cells Mol Dis 2016; 57:8-12.
32. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014; 64:1128-1139.
33. Pollack CV Jr. Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J 2016; 33:423-430.
34. Kutcher ME, Redick BJ, McCreery RC, Crane IM, Greenberg MD, Cachola LM et al. Characterization of platelet dysfunction after trauma. J Trauma Acute Care Surg 2012; 73:13-19.
35. Adamzik M, Gorlinger K, Peters J, Hartmann M. Whole blood impedance aggregometry as a biomarker for the diagnosis and prognosis of severe sepsis. Crit Care 2012; 16:R204.
36. Ramaker AJDWR, Meyer P, van der Meer J, Struys MMRF, Lisman T, van Oeveren W, Hendriks HGD. Effects of acidosis, alkalosis, hyperthermia and hypothermia on haemostasis: results of point-of-care testing with the thromboelastography analyser. Blood Coagul Fibrinolysis 2009; 20:436-439.
37. Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 Suppl 1:S61-S65.
38. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85:958-965.
39. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21:131-142.
40. Brass LF. Thrombin and platelet activation. Chest 2003; 124: 18S-25S.
41. Nachmias VT, Kavaler J, Jacubowitz S. Reversible association of myosin with the platelet cytoskeleton. Nature 1985; 313:70-72.
42. Duvernay M, Young S, Gailani D, Schoenecker J, Hamm HE. Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets. Mol Pharmacol 2013; 83:781-792.
43. Aleman MM, Byrnes JR, Wang J-G, Tran R, Lam WA, Di Paola J et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest 2014; 124:3590-3600.
44. Cines DB, Lebedeva T, Nagaswami C, Hayes V, Massefski W, Litvinov RI et al. Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood 2014; 123:1596-1603.
45. Tutwiler V, Litvinov RI, Lozhkin A P, Peshkova AD, Lebedeva T, Ataullakhanov FI et al. Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood. Blood 2016; 127:149-159.
46. Perel P, Clayton T, Altman DG, Croft P, Douglas I, Hemingway H et al. Red blood cell transfusion and mortality in trauma patients: risk-stratified analysis of an observational study. PLoS Med 2014; 11:e1001664.
47. Lewis JC, Hantgan RR, Stevenson SC, Thornburg T, Kieffer N, Guichard J, Breton-Gorius J. Fibrinogen and glycoprotein IIb/IIIa localization during platelet adhesion. Localization to the granulomere and at sites of platelet interaction. Am J Pathol 1990; 136:239-252.
48. Hagemo JS, Stanworth S, Juffermans NP, Brohi K, Cohen M, Johansson PI et al. Prevalence, predictors and outcome of hypofibrinogenaemia in trauma: a multicentre observational study. Crit Care 2014; 18:R52.
49. Haas T, Spielmann N, Restin T, Seifert B, Henze G, Obwegeser J et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: A prospective randomised controlled trial. Br J Anaesth 2015; 115:234-243.
50. 9/L. Blood Transfus 2015; 13:248-254.
51. Basra SS, Tsai P, Lakkis NM. Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. J Am Coll Cardiol 2011; 58:2263-2269.
52. Weiss HJ. Flow-related platelet deposition on subendothelium. Thromb Haemost 1995; 74:117-122.
53. Joseph B, Aziz H, Pandit V, Hays D, Kulvatunyou N, Yousuf Z et al. Prothrombin complex concentrate versus fresh-frozen plasma for reversal of coagulopathy of trauma: is there a difference? World J Surg 2014; 38:1875-1881.
54. Joseph B, Pandit V, Khalil M, Kulvatunyou N, Aziz H, Tang A et al. Use of prothrombin complex concentrate as an adjunct to fresh frozen plasma shortens time to craniotomy in traumatic brain injury patients. Neurosurgery 2015; 76:601-607.
55. Kauvar DS, Holcomb JB, Norris GC, Hess JR. Fresh whole blood transfusion: a controversial military practice. J Trauma 2006; 61:181-184.
56. Ho KM, Leonard AD. Lack of effect of unrefrigerated young whole blood transfusion on patient outcomes after massive transfusion in a civilian setting. Transfusion 2011; 51:1669-1675.
57. Johansson PI, Hansen MB, Sorensen H. Transfusion practice in massively bleeding patients: time for a change? Vox Sang 2005; 89:92-96.
58. Johansson PI, Bochsen L, Stensballe J, Secher NH. Transfusion packages for massively bleeding patients: the effect on clot formation and stability as evaluated by Thrombelastograph (TEG). Transfus Apher Sci 2008; 39:3-8.
59. Johansson PI, Stensballe J, Rosenberg I, Hilslov TL, Jorgensen L, Secher NH. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion 2007; 47:593-598.
60. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarzabal LA, Schreiber MA et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248:447-458.
61. Ball CG, Dente CJ, Shaz B, Wyrzykowski AD, Nicholas JM, Kirkpatrick AW, Feliciano DV. The impact of a massive transfusion protocol (1:1:1) on major hepatic injuries: does it increase abdominal wall closure rates? Can J Surg 2013; 56:E128-E134.
62. Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technol Assess 2015; 19:1-228.
63. Gando S, Hayakawa M. Pathophysiology of trauma-induced coagulopathy and management of critical bleeding requiring massive transfusion. Semin Thromb Hemost 2016; 42:155-165.
64. Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood 2015; 125:1387-1393.
65. Kornblith LZ, Kutcher ME, Redick BJ, Calfee CS, Vilardi RF, Cohen MJ. Fibrinogen and platelet contributions to clot formation: implications for trauma resuscitation and thromboprophylaxis. J Trauma Acute Care Surg 2014; 76: 255-256.
66. Topf H-G, Weiss D, Lischetzki G, Strasser E, Rascher W, Rauh M. Evaluation of a modified thromboelastography assay for the screening of von Willebrand disease. Thromb Haemost 2011; 105:1091-1099.
67. Rosengart TK, Romeiser JL, White LJ, Fratello A, Fallon E, Senzel L, Shroyer AL. Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration. J Thorac Cardiovasc Surg 2013; 146:1259-1266.
68. Pearse BL, Smith I, Faulke D, Wall D, Fraser JF, Ryan EG et al. Protocol guided bleeding management improves cardiac surgery patient outcomes. Vox Sang 2015; 109:267-279.
69. Agarwal S, Johnson RI, Shaw M. Preoperative point-of-care platelet function testing in cardiac surgery. J Cardiothorac Vasc Anesth 2015; 29:333-341.
70. Lynch AM, deLaforcade AM, Meola D, Shih A, Bandt C, Guerrero NH, Ricco C. Assessment of hemostatic changes in a model of acute hemorrhage in dogs. J Vet Emerg Crit Care (San Antonio) 2016; 26:333-343.
71. White NJ, Contaifer D Jr, Martin EJ, Newton JC, Mohammed BM, Bostic JL et al. Early hemostatic responses to trauma identified with hierarchical clustering analysis. J Thromb Haemost 2015; 13:978-988.
72. Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag 2015; 11: 133-148.
73. Mazzeffi M, Szlam F, Jakubowski JA, Tanaka KA, Sugidachi A, Levy JH. In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel. Thromb Res 2013; 132:106-111.
74. Szlam F, Tanaka KA, Rumph B, Bolliger D, Levy JH. In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition. Thromb Haemost 2010; 103: 863-865.
75. Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME. Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. Anesth Analg 2011; 113:703-710.
76. Van Poucke S, Stevens K, Kicken C, Simons A, Marcus A, Lance M. Platelet function during hypothermia in experimental mock circulation. Artif Organs 2016; 40:288-293.
77. Ho KM, Yip CB. Concentration-dependent effect of hypocalcaemia on in vitro clot strength in patients at risk of bleeding: a retrospective cohort study. Transfus Med 2016; 26:57-62.
78. Davlouros P, Xanthopoulou I, Mparampoutis N, Giannopoulos G, Deftereos S, Alexopoulos D. Role of calcium in platelet activation: novel insights and pharmacological implications. Med Chem 2016; 12:131-138.
79. Tynngard N, Lindahl TL, Ramstrom S. Assays of different aspects of haemostasis-what do they measure? Thromb J 2015; 13:8.
80. Srivastava A, Kelleher A. Point-of-care coagulation testing. Contin Educ Anaesth Crit Care Pain 2012. doi: 10.1093/bjaceaccp/mks049 (available at http://ceaccp.oxfordjournals.org/content/13/1/12.full.pdf). Accessed on June 24, 2016.
81. Solbeck S, Ostrowski SR, Stensballe J, Johansson PI. Thrombelastography detects dabigatran at therapeutic concentrations in vitro to the same extent as gold-standard tests. Int J Cardiol 2016; 208:14-18.
82. Adelmann D, Wiegele M, Wohlgemuth RK, Koch S, Frantal S, Quehenberger P et al. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. Thromb Res 2014; 134:918-923.
83. Ho KM, Ismail H. Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis. Anaesth Intensive Care 2003; 31:529-537.
84. Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess 2013; 17:1-79.
85. Murphy CH, Hess JR. Massive transfusion: red blood cell to plasma and platelet unit ratios for resuscitation of massive hemorrhage. Curr Opin Hematol 2015; 22:533-539.
86. Johansson PI, Stensballe J, Oliveri R, Wade CE, Ostrowski SR, Holcomb JB. How I treat patients with massive hemorrhage. Blood 2014; 124:3052-3058.
87. Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 2016; 62:699-707.